RPRX
Royalty Pharma plc
Latest Form 4:Sale$6.0MbyHite Christopher (EVP & Chairman, Partnering) · filed Aug 19, 2026
Royalty Pharma plc (RPRX) has 64 SEC Form 4 filings (101 transaction rows) in the rolling window, disclosed by 5 distinct insiders. Most recent filing: Aug 19, 2026.
The most active filer is EVP & CFO Coyne Terrance P. with 16 filings. Insiders have net sold $36.4M over the trailing 6 months.
- Industry:Medical - Pharmaceuticals
- CEO:Pablo Legorreta
- Employees:100
- HQ:New York, NY, US
- IPO:2020-06-16
Insider Buying
$0
reported purchases (SEC code P)
Insider Selling
$86.5M
reported sales (SEC code S)
Unique Insiders
5
in the rolling window
Market Cap
$33.9B
latest known value
| Source | ||||||
|---|---|---|---|---|---|---|
| EVP & Chairman, Partnering | Sale | 100,000 | $6.0M | Aug 19 | SEC ↗ | |
| EVP & CFO | Sale | 11,002 | $646K | Aug 17 | SEC ↗ | |
| EVP & Chairman, Partnering | Sale | 130,000 | $7.3M | Jul 2 | SEC ↗ | |
| EVP, Research & Investments | Sale | 9,099 | $508K | Jul 2 | SEC ↗ | |
Hite ChristopherFirst filing | EVP & Chairman, Partnering | Sale | 150,000 | $8.2M | Jun 25 | SEC ↗ |
| EVP, Research & Investments | Sale | 9,098 | $502K | Jun 25 | SEC ↗ | |
| EVP & CFO | Sale | 64,399 | $3.5M | May 28 | SEC ↗ | |
| EVP, Research & Investments | Sale | 13,684 | $722K | May 22 | SEC ↗ | |
Urist MarshallFirst in 3 months | EVP, Research & Investments | Sale | 13,684 | $726K | May 15 | SEC ↗ |
Norden GregoryFirst filing | Director | Sale | 3,045 | $161K | May 15 | SEC ↗ |
| EVP & CFO | Sale | 34,791 | $1.7M | Apr 30 | SEC ↗ | |
| EVP & CFO | Sale | 34,791 | $1.7M | Apr 2 | SEC ↗ | |
| EVP & CFO | Sale | 34,791 | $1.6M | Mar 25 | SEC ↗ | |
| EVP & CFO | Sale | 34,791 | $1.6M | Mar 4 | SEC ↗ | |
| EVP & CFO | Sale | 34,791 | $1.6M | Feb 25 | SEC ↗ | |
| EVP & CFO | Sale | 108,424 | $4.6M | Feb 4 | SEC ↗ | |
| EVP & CFO | Sale | 114,954 | $4.9M | Feb 4 | SEC ↗ | |
| EVP & CFO | Sale | 20,163 | $873K | Feb 4 | SEC ↗ | |
| EVP, Research & Investments | Sale | 20,000 | $822K | Feb 2 | SEC ↗ | |
| EVP, Research & Investments | Sale | 20,000 | $805K | Jan 26 | SEC ↗ | |
| EVP & CFO | Sale | 69,582 | $2.7M | Jan 23 | SEC ↗ | |
| EVP, Research & Investments | Sale | 20,000 | $790K | Jan 20 | SEC ↗ | |
| EVP, Research & Investments | Sale | 20,000 | $816K | Jan 13 | SEC ↗ | |
| EVP & CFO | Sale | 69,582 | $2.7M | Jan 6 | SEC ↗ | |
| EVP, Research & Investments | Sale | 20,000 | $770K | Jan 6 | SEC ↗ | |
| EVP, Research & Investments | Sale | 20,000 | $786K | Dec 29 | SEC ↗ | |
| EVP, Research & Investments | Sale | 20,000 | $768K | Dec 22 | SEC ↗ | |
| EVP, Investments & CLO | Sale | 79,346 | $3.1M | Dec 19 | SEC ↗ | |
| EVP, Investments & CLO | Sale | 30,654 | $1.2M | Dec 19 | SEC ↗ | |
| EVP & CFO | Sale | 69,582 | $2.7M | Dec 17 | SEC ↗ | |
| EVP, Research & Investments | Sale | 20,000 | $766K | Dec 17 | SEC ↗ | |
| EVP, Research & Investments | Sale | 41,576 | $1.6M | Dec 9 | SEC ↗ | |
| EVP, Investments & CLO | Sale | 110,000 | $4.4M | Dec 5 | SEC ↗ | |
Urist MarshallFirst filing | EVP, Research & Investments | Sale | 41,575 | $1.7M | Dec 3 | SEC ↗ |
| EVP & CFO | Sale | 69,582 | $2.8M | Dec 3 | SEC ↗ | |
| EVP & CFO | Sale | 69,582 | $2.7M | Nov 26 | SEC ↗ | |
Lloyd George W.First filing | EVP, Investments & CLO | Sale | 135,426 | $5.2M | Nov 21 | SEC ↗ |
Coyne Terrance P.First filing | EVP & CFO | Sale | 69,594 | $2.7M | Nov 19 | SEC ↗ |
Related companies
Royalty Pharma plc is in the Healthcare sector.